导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.16% | 1337/4345 |
| 近一周 | -1.29% | 1770/4962 |
| 近一月 | -8.69% | 4580/4922 |
| 近一季 | -19.11% | 4423/4747 |
| 近半年 | -0.59% | 1380/4477 |
| 近一年 | 8.27% | 1239/4016 |
| 近两年 | 119.76% | 395/2712 |
| 近三年 | 70.37% | 317/2054 |
| 成立以来 | 100.53% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.57% 1855/4961 |
37.11% 855/5312 |
- - |
- - |
| 2025 | 51.30% 442/4813 |
-1.70% 2751/3635 |
3.31% 1054/4076 |
50.37% 310/4524 |
-0.93% 2726/4813 |
| 2024 | 14.58% 1036/3463 |
-3.90% 1579/2808 |
-6.44% 1950/3014 |
29.40% 162/3129 |
-1.52% 1737/3463 |
| 2023 | -18.86% 1832/2656 |
2.19% 1415/2280 |
-7.05% 1765/2385 |
-9.40% 1810/2515 |
-5.72% 1474/2655 |
| 2022 | -29.13% 1590/2207 |
-19.87% 1502/1919 |
5.64% 852/2016 |
-18.35% 1699/2113 |
2.55% 902/2208 |
| 2021 | 12.84% 373/1822 |
-7.05% 1054/1255 |
26.55% 69/1330 |
-6.43% 928/1466 |
2.52% 572/1822 |
| 2020 | 65.65% 93/1250 |
3.79% 107/1028 |
30.65% 49/1067 |
5.93% 890/1164 |
15.32% 220/1184 |
| 2019 | 44.42% 172/1092 |
35.56% 92/754 |
-10.02% 711/804 |
7.41% 89/850 |
10.23% 152/918 |
| 2018 | -27.08% 414/834 |
- - |
- - |
- - |
-11.12% 251/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发创业板ETF VS. 长安沪深300非周期A(740101) |